Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Year End Q4 Financials

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Jun 19, 2022 7:37pm

218 Views

Post# 34767873

Year End Q4 Financials

possibly out end of the month (june/28th last year) maybe we get an update.

Bolstering intellectual property (“IP”) position

Filed new patent application covering uses of otenaproxesul for treatment of acute pain; potential for IP protection to extend into the 2040s
Filed trademark applications in all major markets for two proprietary brand names

Upcoming Milestones

The following summarizes the Company’s estimated timeline for its key upcoming milestones (calendar quarters):